---
title: "SANAI HEALTH GP issues a profit warning, expecting a loss of approximately 25.5 million to 27.5 million yuan for the fiscal year 2025"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/280822851.md"
description: "SANAI HEALTH GP issued a profit warning, expecting to incur a loss of approximately 25.5 million to 27.5 million yuan by December 31, 2025, while achieving a profit of about 3.4 million yuan in the same period of 2024. The reasons for the loss include: losses from the sale of subsidiaries, reduced gross profit, and increased distribution costs and administrative expenses"
datetime: "2026-03-27T16:15:02.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/280822851.md)
  - [en](https://longbridge.com/en/news/280822851.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/280822851.md)
---

# SANAI HEALTH GP issues a profit warning, expecting a loss of approximately 25.5 million to 27.5 million yuan for the fiscal year 2025

According to the Zhitong Finance APP, SANAI HEALTH GP (01889) announced that it expects to incur a loss ranging from RMB 25.5 million to RMB 27.5 million for the year ending December 31, 2025, compared to a profit of approximately RMB 3.4 million for the same period in 2024.

The expected shift from profit in 2024 to loss in 2025 is mainly due to: (i) the company expects to incur a net loss of approximately RMB 800,000 from the sale of subsidiaries in 2025, while in the same period of 2024, it recorded a one-time non-recurring gain of approximately RMB 17.1 million from the sale of subsidiaries; (ii) compared to the same period in 2024, the company expects a decrease in gross profit of approximately RMB 2.5 million in 2025, mainly due to the continuous rise in the cost of traditional Chinese medicinal materials, which has outpaced the increase in the selling price of the company's end products; (iii) the company has recorded an increase in distribution costs and administrative expenses totaling approximately RMB 5 million during this period, mainly attributed to Beijing Hangyang Health Technology Co., Ltd. and its subsidiaries, with a significant portion not recorded in the same period of 2024

### Related Stocks

- [01889.HK](https://longbridge.com/en/quote/01889.HK.md)

## Related News & Research

- [Green Cross Health Brings Forward AGM to Combine With Medical Division Sale Vote](https://longbridge.com/en/news/290640370.md)
- [Germany's Merz aims to pass pension reform by year end](https://longbridge.com/en/news/290697633.md)
- [Fusen Pharmaceutical Wins China Nod for Peramivir Flu Injection](https://longbridge.com/en/news/290914836.md)
- [Soitec says CDC beneficial stake falls to 12.16% of capital, 17.84% voting rights](https://longbridge.com/en/news/290845925.md)
- [Abbisko Showcases Promising Phase II FGFR2-Targeted Combo Data in Advanced Gastric Cancer](https://longbridge.com/en/news/290916600.md)